6.
Langermann S, Palaszynski S, Sadziene A, Stover C, Koenig S
. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature. 1994; 372(6506):552-5.
DOI: 10.1038/372552a0.
View
7.
Chen G, Yang Y, Gao X, Dou Y, Wang H, Han G
. Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenzene sulfonic acid induced model of colitis. Lab Invest. 2010; 91(3):472-83.
DOI: 10.1038/labinvest.2010.183.
View
8.
Wu Y, Kelly S, Sanchez-Perez L, Sampson J, Collier J
. Comparative study of α-helical and β-sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes. Biomater Sci. 2020; 8(12):3522-3535.
PMC: 7665831.
DOI: 10.1039/d0bm00521e.
View
9.
Wu Y, Norberg P, Reap E, Congdon K, Fries C, Kelly S
. A Supramolecular Vaccine Platform Based on α-Helical Peptide Nanofibers. ACS Biomater Sci Eng. 2019; 3(12):3128-3132.
PMC: 6364304.
DOI: 10.1021/acsbiomaterials.7b00561.
View
10.
Jain U, Woodruff T, Stadnyk A
. The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10. Br J Pharmacol. 2012; 168(2):488-501.
PMC: 3572573.
DOI: 10.1111/j.1476-5381.2012.02183.x.
View
11.
Jeyanathan M, Vaseghi-Shanjani M, Afkhami S, Grondin J, Kang A, DAgostino M
. Parenteral BCG vaccine induces lung-resident memory macrophages and trained immunity via the gut-lung axis. Nat Immunol. 2022; 23(12):1687-1702.
PMC: 9747617.
DOI: 10.1038/s41590-022-01354-4.
View
12.
Ruane D, Chorny A, Lee H, Faith J, Pandey G, Shan M
. Microbiota regulate the ability of lung dendritic cells to induce IgA class-switch recombination and generate protective gastrointestinal immune responses. J Exp Med. 2015; 213(1):53-73.
PMC: 4710201.
DOI: 10.1084/jem.20150567.
View
13.
Gu H, Mickler E, Cummings O, Sandusky G, Weber D, Gracon A
. Crosstalk between TGF-β1 and complement activation augments epithelial injury in pulmonary fibrosis. FASEB J. 2014; 28(10):4223-34.
PMC: 4202097.
DOI: 10.1096/fj.13-247650.
View
14.
Ainai A, Suzuki T, Tamura S, Hasegawa H
. Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate. Viral Immunol. 2017; 30(6):451-462.
DOI: 10.1089/vim.2017.0022.
View
15.
Wu Y, Wen H, Bernstein Z, Hainline K, Blakney T, Congdon K
. Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses. Sci Adv. 2022; 8(29):eabm7833.
PMC: 9299545.
DOI: 10.1126/sciadv.abm7833.
View
16.
Stark K, Massberg S
. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol. 2021; 18(9):666-682.
PMC: 8100938.
DOI: 10.1038/s41569-021-00552-1.
View
17.
Kar S, Devnath P, Emran T, Tallei T, Mitra S, Dhama K
. Oral and intranasal vaccines against SARS-CoV-2: Current progress, prospects, advantages, and challenges. Immun Inflamm Dis. 2022; 10(4):e604.
PMC: 8959423.
DOI: 10.1002/iid3.604.
View
18.
Hainline K, Shores L, Votaw N, Bernstein Z, Kelly S, Fries C
. Modular complement assemblies for mitigating inflammatory conditions. Proc Natl Acad Sci U S A. 2021; 118(15).
PMC: 8054013.
DOI: 10.1073/pnas.2018627118.
View
19.
Dunkelberger J, Song W
. Complement and its role in innate and adaptive immune responses. Cell Res. 2009; 20(1):34-50.
DOI: 10.1038/cr.2009.139.
View
20.
Dubois E, Cohen A
. Eculizumab. Br J Clin Pharmacol. 2009; 68(3):318-9.
PMC: 2766470.
DOI: 10.1111/j.1365-2125.2009.03491.x.
View